- June 07, 2022
Creating a Road Map to Cure Pulmonary Fibrosis
- May 25, 2022
Yale-PCCSM Members Honored by American Thoracic Society
- February 09, 2022
Scientists Apply High-resolution, Single-cell Profiling to Understand Immune Response in Severe COVID-19
- January 27, 2022Source: YaleNews
Researchers Produce a Cellular Blueprint of COPD
- May 25, 2021Source: YaleNews
Researchers Create Cellular Blueprint of Healthy Lungs
Welcome to The Kaminski Lab!
Dr Kaminski’s research is currently focused on improving our understanding and treatment of chronic lung diseases such as Idiopathic Pulmonary Fibrosis (IPF), a chronic lung disease characterized by progressive scarring of the lungs, as well as COPD, Sarcoidosis and Asthma. His group applies cutting edge high throughput technologies that measure changes in the sequence, expression or regulation of all the genes in the human genome to identify the mechanisms, improve the diagnosis and develop new therapeutic targets.
While lung diseases have traditionally been defined by objective clinical characteristics, these characteristics usually do not predict outcome, response to therapy and morbidity and mortality. To realize the promise of personalized medicine, the current diagnostic approaches to chronic lung diseases should be modified to include both information on the genetics, epigenetics and microbiome of the individual and the diseased organ as well dynamic molecular information that can more precisely define the etiology, stage, and the biological activity of the disease process.
Principal Investigator
Naftali Kaminski, MD
Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)